SCYNEXIS announced the presentation of interim data across a diverse array of infection types from its ongoing Phase 3 FURI and CARES studies, as well as the innovative study design of its ongoing Phase 3 MARIO trial of oral ibrexafungerp treatment after an intravenous echinocandin, at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases, ECCMID, being held in Copenhagen, Denmark, April 15-18, 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SCYX:
- SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark
- Scynexis price target raised to $9 from $8 at Guggenheim
- ‘Lots to like’ about Scynexis post-Q4, GSK deal, says Cantor Fitzgerald
- SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
- Scynexis reports FY22 EPS ($1.47), consensus ($1.52)
